Author: Michelle Prudhomme

Advances in Anticancer Agents in Medicinal Chemistry

Volume 2

eBook: US $39 Special Offer (PDF + Printed Copy): US $162
Printed Copy: US $143
Library License: US $156
ISSN: 2589-2819 (Print)
ISSN: 2214-4331 (Online)
ISBN: 978-1-60805-715-3 (Print)
ISBN: 978-1-60805-496-1 (Online)
Year of Publication: 2013
DOI: 10.2174/97816080549611130201


Advances in Anticancer Agents in Medicinal Chemistry is an exciting eBook series comprising a selection of updated articles previously published in the peer-reviewed journal Anti-Cancer Agents in Medicinal Chemistry. The second Volume of this eBook series gathers updated reviews on several classes of molecules exhibiting anticarcinogenic potential as well as some important targets for the development of novel anticancer drugs.

Featured Anti-cancer molecules:

  • - Marine macrolides and their biological targets
  • - Organometallic supramolecular complexes including gold-based anticancer agents, anti-cancer vaccines
  • - glyconanoparticles,
  • - isatin-based compounds,
  • - tripentone families of potential anticancer drugs

Drug targets in this volume include:

  • - selective estrogen receptor modulators,
  • - leukemia stem cells,
  • - glioblastoma cell migratory mechanisms
  • - Tyrosyl-DNA phosphodiesterase 1

Advances in Anticancer Agents in Medicinal Chemistry will be of particular interest to readers interested in anticancer drug therapy as the series provides relevant reviews written by experts in this important field.

Indexed in: Book Citation Index, Science Edition, EBSCO, Ulrich's Periodicals Directory.


This eBook in the Advances in Anticancer Agents in Medicinal Chemistry series continues the concept put together so well in the first volume of the series. By drawing on original articles published during 2008-2010 in Anticancer Agents in Medicinal Chemistry, and having them updated, the volume provides up-to-date reviews on a wide range of drug classes, including marine macrolides, metalbased complexes and glycoconjugate-based vaccines. Also discussed are biological targets through which to control leukemia stem cells, mitosis, metastasis, DNA repair and estrogen receptor modulation. Michelle Prudhomme, Editor-in-Chief of Anticancer Agents in Medicinal Chemistry, is to be commended for this new series, and for the selection of such a wide-ranging set of interesting reviews in Volume 2.

William A. Denny
Auckland Cancer Society Research Centre
University of Auckland
New Zealand